



**HAL**  
open science

## Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters

H. Syrjälä, P. Ohtonen, U. Kinnunen, R. Rätty, E. Elonen, T. Nousiainen, E. Jantunen, K. Remes, M. Itälä-Remes, R. Silvennoinen, et al.

### ► To cite this version:

H. Syrjälä, P. Ohtonen, U. Kinnunen, R. Rätty, E. Elonen, et al.. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. *European Journal of Clinical Microbiology and Infectious Diseases*, 2010, 29 (10), pp.1211-1218. 10.1007/s10096-010-0984-1 . hal-00601168

**HAL Id: hal-00601168**

**<https://hal.science/hal-00601168v1>**

Submitted on 17 Jun 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Editorial Manager(tm) for European Journal of Clinical Microbiology & Infectious  
Diseases  
Manuscript Draft

Manuscript Number: EJCMIID-D-09-00668R2

Title: Blood Stream Infections during Chemotherapy-Induced Neutropenia in Adult Patients with Acute Myeloid Leukemia: Treatment cycle matters

Article Type: Article

Keywords: acute myeloid leukemia, adult, chemotherapeutics, neutropenia, bloodstream infection

Corresponding Author: Mr. Urpo Kinnunen, M.D.

Corresponding Author's Institution: Lapland Central Hospital

First Author: Hannu Syrjälä

Order of Authors: Hannu Syrjälä; Pasi Ohtonen; Urpo Kinnunen, M.D.; Rätty Riikka; Erkki Elonen; Tapio Nousiainen; Esa Jantunen; Kari Remes; Maija Itälä-Remes; Raija Silvennoinen; Pirjo Koistinen

Abstract: Purpose: To assess the frequency of bloodstream infections (BSI) during neutropenia in different cycles (C) of intensive chemotherapy treatment in acute myeloid leukemia (AML).

Methods: Register data of 327 consecutive patients aged 16-66 years having de novo AML between September 1992 and December 2001 was prospectively gathered.

Results: There were 956 treatment episodes with 456 (47.7%) positive blood cultures. BSI was monomicrobial in 327 episodes (71.7%) and polymicrobial in 129 (28.3%). The overall incidence rate (per 1000 hospital days) for BSI was 13.2, varying from 6.8 in CI after idarubicin, cytarabine and thioquanine to 15.6 in CII, 15.8 in CIII and 17.6 in CIV. The distribution of monomicrobial gram-positive BSIs was as follows: CI; 71.7%, CII; 62.8%, CIII; 53.3%, CIV; 36.6% and C I-IV together; 43.2%. The most common finding in the four different cycles was coagulase-negative staphylococci (38.3% to 30.6%). Viridans group streptococci were most commonly observed (in 20.4% of positive blood cultures) during CII after high-dose cytarabine and idarubicin treatments. The distribution of monomicrobial gram-negative BSIs was as follows: CI; 21.7%, CII; 36.3%, CIII; 45.7%, CIV; 46.9%, and CI-IV together; 37.9%.

Conclusions: It would be more reasonable to analyze chemotherapy cycle-based BSI results rather than overall results.

Response to Reviewers: Answers for the reviewers

We have changed the text in lines 207 -210 just to improve language.

Reviewer #1:

We agree with the reviewer: due to the register data we could not exclude the possibility, that two or more different micro-organisms found during a chemotherapy cycle did not represent two or more separate episodes of BSI.

"If more than one micro-organism was recovered from blood cultures of a patient during a chemotherapy cycle, the episode was defined as polymicrobial." is added to the method section in lines 115 - 116.

Reviewer #2:

We agree with the reviewer, that the cycle II is a crucial point in the data. As suggested we analyzed the cycle 2 by dividing it in two groups: those with active disease and receiving the 2nd induction (n=80) and those in remission and receiving the 1st consolidation (n=212).

	Active disease	Remission	p	(n=80)	(n=212)
Neutropenia d	27(22 - 36)	25(19 - 31)	NS		
Febrile d	8 (4.5 - 11)	6 (3 - 11)	NS		
peak CRP-value	162(123 - 215)	159.5(110 - 202)	NS		
GI-tox 3&4	37.3 %	29.1 %	0.194		
CoNS	25 %	22 %	NS		
VGS	11 %	20 %	0.119		
Enterococci	9 %	11 %	NS		
E.coli	4 % 6 %	NS			
Klebsiella	8 %	11 %	NS		
Enterobacter	6 %	6 %	NS		
Citrobacter	0	3 %	NS		
Pseudomonas	4 %	3 %	NS		

We could not demonstrate any significant differences between the groups. This may partly be due to the limited number of patients (80 + 212). A more powerful study would probably demonstrate difference in amount of VGS and maybe in amount of gastrointestinal toxicity.

The following sentence has been added into the text in the results section to lines 157 - 159: "On the other hand, no difference in number of febrile or neutropenic days, in amount of grade 3 & 4 gastrointestinal toxicity, peak CRP-values, or recovery of individual microbial strains was found between those patients with active disease and those in remission in the second cycle".

The reviewer asks about the interpretation about the skin contaminants found in blood cultures. Due to the characteristics of the register data we cannot analyze more specifically these blood culture findings. Unfortunately we have to accept decisions of attending physicians.

We have changed the text about interpretation of blood cultures in the methods section: "Whether blood culture findings were true or contaminant was accepted by attending physicians." is added to the text in the line 114.

The reviewer points to the possible inability of the WHO criteria to detect gastrointestinal toxicity caused by chemotherapy. "Another explanation to our surprising findings may be that measuring toxicity by the WHO method is not sensitive enough for identifying this kind of changes in gastrointestinal tract." is added in the text into the discussion section to lines 212 - 214.

The question, whether the patients who died, did so before acquiring BSI was analyzed in cycles one and two: During the first cycle 13 patients died of whom BSI data of 11 patients were available and five had BSI. During the second cycle, eleven patients with induction treatment died, of whom eight had BSI. Taken together, the interesting idea made by the reviewer, did not seem to explain our results.

1 **Blood Stream Infections during Chemotherapy-Induced**  
2  
3 **Neutropenia in Adult Patients with Acute Myeloid Leukemia:**  
4  
5  
6 **Treatment cycle matters**  
7

8  
9  
10  
11  
12 5 Hannu Syrjälä,<sup>1\*</sup> Pasi Ohtonen,<sup>2#</sup> Urpo Kinnunen,<sup>3#</sup> Riikka Rätty,<sup>4</sup> Erkki Elonen,<sup>4</sup> Tapio  
13  
14 6 Nousiainen,<sup>5</sup> Esa Jantunen,<sup>5</sup> Kari Remes,<sup>6</sup> Maija Itälä-Remes,<sup>7</sup> Raija Silvennoinen<sup>7</sup> and Pirjo  
15  
16  
17 7 Koistinen,<sup>8</sup> for the Finnish Leukemia Group.  
18

19 8  
20  
21  
22 9 <sup>1</sup>Department of Infection Control, and <sup>2</sup>Departments of Surgery and Anesthesiology Oulu  
23  
24 10 University Hospital, Oulu, <sup>3</sup> Department of Medicine, Lapland Central Hospital, Rovaniemi,  
25  
26 11 <sup>4</sup>Department of Medicine, Helsinki University Central Hospital, Helsinki, <sup>5</sup>Department of  
27  
28 12 Medicine, Kuopio University Hospital, Kuopio, <sup>6</sup>Department of Medicine, Turku University  
29  
30 13 Central Hospital, Turku, <sup>7</sup>Department of Medicine, Tampere University Hospital, Tampere,  
31  
32 14 and <sup>8</sup>Department of Medicine, Oulu University Hospital, Oulu, Finland.  
33

34 15 # These authors have an equal distribution to the work.  
35  
36  
37  
38  
39 16  
40  
41 17  
42

43 18 **\*Corresponding author:**

44 19 Dr. Urpo Kinnunen

45  
46 20 Lapland Central Hospital

47  
48 21 Box 8041,

49 22  
50 23 FIN-96101 Rovaniemi  
51 24

52 25 Phone:-358-400-254885  
53 26

54 27 E-mail: urpo.kinnunen@oulu.fi  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

27

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

28 **Appendix**

29

30 The other investigators and centers of the Finnish Leukemia Group collaborated in this study:

31 Liisa Volin and Tapani Ruutu, Helsinki; Timo Siitonen and Eeva-Riitta Savolainen, Oulu;

32 Vesa Lindström, Tampere; Tarja-Terttu Pelliniemi, Turku.

33

34 **ABSTRACT**

35

36 **Purpose:** To assess the frequency of bloodstream infections (BSI) during neutropenia in  
37 different cycles of intensive chemotherapy treatment in acute myeloid leukemia (AML).

38 **Methods:** Register data of 327 consecutive patients aged 16-66 years having *de novo* AML  
39 between September 1992 and December 2001 was prospectively gathered in five Finnish  
40 tertiary care leukemia centers. The patients had not received fluoroquinolone prophylaxis.  
41 Reported BSI rates were compared during neutropenia in four chemotherapy treatment cycles  
42 (C).

43 **Results:** There were 956 treatment episodes with 456 (47.7%) positive blood cultures. BSI  
44 was monomicrobial in 327 episodes (71.7%) and polymicrobial in 129 (28.3%). The overall  
45 incidence rate (per 1000 hospital days) for BSI was 13.2, varying from 6.8 in CI after  
46 idarubicin, conventional-dose cytarabine and thioquanine to 15.6 in CII, 15.8 in CIII and 17.6  
47 in CIV. The distribution of monomicrobial gram-positive BSIs was as follows: CI; 71.7%,  
48 CII; 62.8%, CIII; 53.3%, CIV; 36.6% and CI-IV together; 43.2%. The most common finding  
49 in the four different cycles was coagulase-negative staphylococci (38.3% to 30.6%). Viridans  
50 group streptococci were most commonly observed (in 20.4% of positive blood cultures)  
51 during CII after high-dose cytarabine and idarubicin treatments. The distribution of  
52 monomicrobial gram-negative BSIs was as follows: CI; 21.7%, CII; 36.3%, CIII; 45.7%,  
53 CIV; 46.9%, and CI-IV together; 37.9%. A great variation of incidence and types of  
54 microorganisms between AML chemotherapy cycles was found.

55 **Conclusions:** It would be more reasonable to analyze chemotherapy cycle-based BSI results  
56 rather than overall results.

57

58 **Key words:** acute myeloid leukemia, adult, chemotherapeutics, neutropenia, bloodstream

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

59 infection

60

61

62

## 63 INTRODUCTION

1  
2 64 As early as in the sixties, the importance of severe gram-negative bacterial blood stream infections (BSI) during  
3  
4 65 intensive chemotherapy of acute myeloid leukemia (AML) was identified [1]. In the seventies, empirical  
5  
6 66 treatment protocols were introduced to treat BSIs caused by gram-negative microorganism in neutropenic fever  
7  
8 67 patients [2]. During the next two decades, the causes of BSIs shifted from gram-negative rods to gram-positive  
9  
10 68 cocci [3, 4, 5, 6, 7, 8, 9]. The most important reason for this change has been explained to be due to the use of  
11  
12 69 antibiotic prophylaxis during periods of neutropenia in AML patients. Interestingly, the newest results suggest  
13  
14 70 that the proportion of gram-negative infections is once again increasing [10].

15  
16 71 According to the knowledge of the authors, little attention has been paid to BSI rate during  
17  
18 72 different chemotherapy cycles. When the febrile episodes of the so called SIGNIFICANT study [11] were later  
19  
20 73 evaluated, it was found that during the chemotherapy of solid tumors and lymphomas the risk of a febrile  
21  
22 74 episode, as a sign of possible BSI and an indication for empirical antibiotic treatment, was highest during the  
23  
24 75 first treatment cycle, especially in testicular and small-cell lung cancers [12]. It was also noted that if the patient  
25  
26 76 had a febrile episode during the first chemotherapy cycle, he or she would have an increased risk of a febrile  
27  
28 77 episode during the subsequent cycles [12].

29  
30 78 In solid tumors and lymphomas patients receive repeated cycles of the same chemotherapeutics,  
31  
32 79 whereas in AML different chemotherapeutics are administrated in consecutive cycles in order to achieve a  
33  
34 80 favorable outcome. As has been seen earlier in a small, one center study, during AML treatment with an  
35  
36 81 idarubicin, conventional-dose cytarabine and thioquanine schedule, the BSI rate was lower than after other  
37  
38 82 regimens [13] whereas high-dose cytarabine treatment was associated with a high BSI rate. The present study  
39  
40 83 was based on the nationwide AML-92 register data collected by the Finnish leukemia group [14], in which 327  
41  
42 84 AML patients with 956 chemotherapy episodes were included for the evaluation of BSI rates. None of the  
43  
44 85 patients had received any antibiotic prophylaxis during chemotherapy-induced neutropenia, which allowed us to  
45  
46 86 observe the real BSI results in four consecutive chemotherapeutic cycles.

47  
48 87

## 50 88 MATERIALS AND METHODS

51  
52 89 **Background.** The study protocol and hematological results of this nationwide study population of 327  
53  
54 90 consecutive intensive chemotherapy-treated patients, of whom 82% experienced complete remission, has earlier  
55  
56 91 been published elsewhere [14].  
57  
58  
59  
60  
61  
62  
63  
64  
65



92 **Study design.** The study protocol is briefly explained as follows (for a more extensive description, see ref. [14]:

1 93 To be included the patient had to have *de novo* AML diagnosed by standard cytological criteria according to  
2  
3 94 French-American-British (FAB) classification [15], and be between 16 and 65 years old. The study protocol was  
4  
5 95 approved by the ethical committees of all five participating centers. Moreover, the National Agency for  
6  
7 96 Medicines scrutinized the protocol before the beginning of the study. All patients provided informed consent.  
8  
9

10 97 During the first induction course the chemotherapeutics used were idarubicin, conventional-dose  
11  
12 98 cytarabine and thioguanine. The second course, which was either first postremission or second induction course,  
13  
14 99 included high-dose cytarabine and idarubicin. The third course included etoposide, high-dose cytarabine and  
15  
16 100 mitoxantrone and the fourth course amsacrine and high-dose cytarabine. The use of supportive treatments (i.e.  
17  
18 101 growth factors, antibiotics, alimentation and blood products) were administered according to the policies of each  
19  
20 102 of the five hematological university centers. All patients had a central venous access. The infections were treated  
21  
22 103 according to generally accepted guidelines [16, 17]. The patients did not receive any antibiotic prophylaxis  
23  
24 104 during chemotherapy-induced neutropenia. For this study the following information was used from the  
25  
26 105 prospectively gathered register data of the AML patients recruited for the original study between September  
27  
28 106 1992 and December 2001: age at the time of diagnosis, sex, treatment faculty, FAB classification of AML,  
29  
30 107 whether or not the patient had an infection at the time of AML diagnosis and whether or not the patient had a  
31  
32 108 positive blood culture (in ten episodes data was missing). Moreover, the duration of hospital stays, neutropenia  
33  
34 109 (days when absolute neutrophil count was less than 500/ $\mu$ L), febrile days (body temperature  $\geq 38$  °C), peak C-  
35  
36 110 reactive protein level (mg/L) and outcome of the patients were analyzed. Furthermore, gastrointestinal toxicity  
37  
38 111 and the severity of infection categorized according to WHO criteria was recorded in each episode [18].  
39

40 112 **Microbiological methods.** Blood was cultured at participating hospitals using automated continuous-  
41  
42 113 monitoring blood culture systems (CMBCS): in two centers with BacT/Alert™ (bioMérieux INDUSTRY,  
43  
44 114 Hazelwood, MS) and in three centers with Bactec 9240™ (BD Diagnostics, Diagnostic Systems, Sparks, MD).  
45  
46 115 The microorganisms were identified by standard microbiological methods based on growth conditions and  
47  
48 116 appearance on solid media, fermentation of sugars and other organic compounds as well as the use of  
49  
50 117 commercial kits. **Whether blood culture findings were true or contaminant was accepted by attending physicians.**  
51  
52 118 **If more than one micro-organism was recovered from blood cultures of a patient during a chemotherapy cycle,**  
53  
54 119 **the episode was defined as polymicrobial.**  
55

56 120 **Statistical analysis.**  
57  
58  
59  
60  
61  
62  
63  
64  
65

121 The summary measurements for continuous and ordinal variables are expressed as medians with 25<sup>th</sup> and 75<sup>th</sup>  
122 percentiles unless otherwise stated. Fisher's exact test was used to analyze simple categorical data. The  
123 generalized linear mixed model approach was utilized in comparison of presence of positive BSI and toxicity in  
124 different chemotherapy cycles and the linear mixed model approach was used when comparing continuous  
125 variables (maximum CRP, duration of neutropenia, length of hospital stay and duration of fever days) between  
126 chemotherapy cycles. Both mixed-model approaches take into account that measurements are repeatedly taken  
127 from the same subjects and these within-subject measurements are not independent [19]. Furthermore, both  
128 methods use all data available, i.e., subjects with missing information are not dropped out from analyses.  
129 Incidence rates (per 1000 hospital days or 1000 neutropenic days) with 95% confidence intervals were  
130 calculated. If the number of hospital days or neutropenic days was missing it was replaced by the cycle average.  
131 Statistical analysis was performed using SPSS (SPSS, version 14.0, SPSS Inc, Chicago, IL) and SAS (version  
132 9.1.3, SAS Institute Inc., Cary, NC) statistical software.

## 133 **RESULTS**

134 **RESULTS**  
135 The study population included 327 AML patients and their most common FAB-types were M2  
136 with 32.1%, M1 with 23.9% and M4 with 23.9%. There were 166 men and 161 women. Their median age was  
137 47.7 yrs with a range from 16 to 66 years of age. More detailed hematological results are presented elsewhere  
138 [14]. WHO grade IV infections with signs of organ failure, were observed among 22 patients in cycle I (6.7%),  
139 12 patients in cycle II (4.1%), 13 patients in cycle III (6.1%) and 9 patients in cycle IV (7.4%).

140 During the study period, there were 40 deaths (12.2%), of which 35 (87.5%) were due to  
141 infection. 12 patients died due to infection during cycle I. Five of these deaths were due to BSIs. Of the 14  
142 patients who died due to infection in cycle II, 10 were treated with the second induction treatment for active  
143 disease. 7 of them had BSI. Only 4 patients treated with consolidation treatment in cycle II died because of  
144 infection. 1 of those infections was BSI. In cycle III, five deaths were due to infections, of which three were  
145 BSIs. In cycle IV four patients died due to infection, with two BSIs among them.

146 In total there were 956 treatment episodes with 456 positive blood cultures, constituting a rate of  
147 47.7% of BSI. The overall incidence rate (per 1000 hospital days) for BSI was 13.2 (95% confidence interval  
148 12.0 to 14.5). When the cycles were compared, the median peak C-reactive protein level did not differ between  
149 the cycles, but the duration of febrile days was longest during the first cycle (Table 1). The length of hospital  
150 stay, the incidence rate for BSI per 1000 patient days or per 1000 neutropenia days were clearly higher in cycles

151 II, III and IV than in cycle I (Table 1). The odds ratio for BSI (compared to cycle I) was 5.8, 5.5 and 4.8 in  
 152 cycles II, III and IV, respectively ( $P < .001$ , in all) (Table 1). Severe gastrointestinal toxicity (WHO grade III and  
 153 IV) was highest during cycle I and decreased significantly in successive cycles, the odds ratios compared to  
 154 cycle I being 0.65 at cycle II ( $P = .041$ ), 0.43 at cycle III ( $P < .001$ ) and 0.33 at cycle IV ( $P < .001$ ) (Table 1,  
 155 Figure 1).

156 During the first chemotherapy cycle, the number of BSI was slightly higher, if the patients did not have  
 157 infections at the time of AML diagnosis (25.6%) than those patients having infections (19.3%,  $P = .17$ ; Figure  
 158 2). During the second cycle, the BSI rate was still slightly higher in the patients who had already achieved  
 159 remission (64.6%) than among those who received the second induction course of chemotherapy (53.6%,  $P =$   
 160 .11; Figure 2). **On the other hand, no difference in number of febrile or neutropenic days, in amount of grade 3 &  
 161 4 gastrointestinal toxicity, peak CRP-values, or recovery of individual microbial strains was found between those  
 162 patients with active disease and those in remission in the second cycle.**

163 There was a great inter-cycle variation among positive blood cultures (from 23.3% to 61.6%) as  
 164 well as for monomicrobial BSIs (from 62.2% to 83.3%) and for polymicrobial BSIs (from 16.7% to 37.2%). In  
 165 monomicrobial BSIs, the proportion of gram-positive microorganisms decreased from cycle I (71.7%) to cycle  
 166 IV (36.6%), whereas the change was in opposite direction among gram-negatives; from 21.7% in cycle I to  
 167 46.9% in cycle IV (Table 2). The most common gram-positive microorganisms in monomicrobial BSIs were  
 168 CoNSs and viridans group streptococci; the latter was most frequently detected during cycle II. The most  
 169 common gram-negative microorganisms were *E. coli* (in cycle III and IV) and *Klebsiella* species (in cycles II  
 170 and III). Anaerobic microorganisms were seen only in cycle I and some yeasts in cycles I-III (table 2).

171 Most polymicrobial BSIs contained two microorganisms (Table 3). The most common  
 172 combination included both gram-positive and gram-negative microorganisms in each cycle (41.8% to 64.3%).  
 173 Although there was once again great variability between the cycles; the proportion of gram-negative  
 174 microorganisms was always higher than 50% (from 52.3% to 82.1%).

175 When the BSI results obtained by two different automated blood systems were compared, there  
 176 was not any statistical difference between them concerning the cycles or individual microorganisms (data not  
 177 shown).

## 179 DISCUSSION

180 Our results show that during the chemotherapy courses of adult AML patients, the BSI rate and yielded  
181 microorganisms vary greatly from cycle to cycle, probably reflecting the tendency of different  
182 chemotherapeutics to predispose patients to infections. Thus, the BSI results in AML should be evaluated based  
183 on cycles rather than on the overall results.

184 Our study has several strengths: It was a prospective multi-center study with a large  
185 homogenous study population of 327 adult *de novo* AML patients treated according to the same schedule of  
186 chemotherapeutic protocol [14]. The patients had not received any prophylactic antibiotics for neutropenia,  
187 which allowed us to study the real influence of different chemotherapeutic cycles on BSI rates during  
188 neutropenia. Our statistical approach with linear and generalized linear mixed models took into account that the  
189 same subjects were evaluated repeatedly, i.e., the measurements of the same patients are not independent. On the  
190 other hand, our register data did not include the detection day of BSI from the onset of neutropenia. The other  
191 weakness of this study was that gathered data did not include the resistance patterns of detected microorganisms  
192 or systematic information regarding the mucositis of the oral cavity of the study subjects.

193 Our BSI proportion of 47.7% is higher than has been thus far reported; the figures in other  
194 studies have varied from 10% to 38.8% [11, 20, 21, 22, 23, 24, 25]. The crucial questions from the point of view  
195 of BSI frequency are study population (only leukemia patients or also patients with solid tumor and lymphomas)  
196 and whether the patients had received antibiotic prophylaxis during neutropenia. For example, in a large multi-  
197 center study with solid tumors and lymphomas, the BSI rate was 6.2% in the levofloxacin group and 7.9% in the  
198 placebo group [11]. In another multi-center study, patients having acute leukemia and a duration of neutropenia  
199 of at least 7 days, BSI rate was 20.6% in the levofloxacin group and 38.8% in the placebo group [21]. In our  
200 study, the median duration of neutropenia was more than three weeks in each cycle, which is a well-known and  
201 real risk of higher BSI rate [1]. In one of our centers, the BSI rate during neutropenia among AML patients  
202 increased from 21% to 40% when a manual blood culture system was replaced by a CMBCS [26]. Taken  
203 together, we consider that our BSI rate is realistic and moreover, our BSI incidence rate of 13.2 per 1000  
204 patient-days is rather near to the corresponding figure of 10.2 published earlier [27].

205 When the BSI results were analyzed separately in each cycle, the recovery of micro-organisms  
206 during the first chemotherapy-induced neutropenia was clearly lower than in other cycles. This phenomenon was  
207 relevant when also incidence rate per 1000 patient-days or per 1000 neutropenia-days was calculated. Our result  
208 was rather surprising, when gastrointestinal toxicity (WHO grade III and IV) was taken into account. High-  
209 dose cytarabine is well-known for its gastrointestinal toxicity. In the present data, the toxicity was highest in the

210 first cycle. It should have been lowest, because the dose of cytarabine in the first cycle was conventional rather  
1 211 than high, as in later cycles. As gastrointestinal toxicity was highest in the first cycle, also the recovery of  
2 212 micro-organisms should have been highest, but that was not the case. We can give no exact explanation for  
3 213 these observations, but we can speculate that leukemia *per se* may have something to do with these findings. In  
4 214 the first cycle all patients had active disease. Altered intestinal permeability and absorption of sugars have been  
5 215 demonstrated in patients with AML even without treatment [28, 29]. Another explanation to our surprising  
6 216 findings may be that measuring toxicity by the WHO method is not sensitive enough for identifying this kind of  
7 217 changes in gastrointestinal tract. On the other hand, in the present data, 63 % of deaths due to infection occurred  
8 218 in patients receiving induction treatment. It seems that outcome of infections is worse among AML patients with  
9 219 active disease than among those who have achieved remission.

20 220           During the last few decades there has been a clear shift from gram-negative BSIs to gram-  
21 221 positive ones in neutropenic infections, which has been suggested to be due to the increased use of intravascular  
22 222 devices, fluoroquinolone prophylaxis and chemotherapy-induced mucositis [9]. When all cycles were analyzed  
23 223 together, in monomicrobial BSIs, the proportion of gram-positive microorganisms was 43.2%, and the  
24 224 proportion of gram-negatives was 37.9%. The corresponding figures in a recent study among patients with  
25 225 hematological malignancies and solid neoplasms in hospitals in the USA with neutrophils of less than 1000/ $\mu$ L  
26 226 were 61% and 24.9%, respectively [8]. In our series, from cycle I to cycle IV, the numbers of gram-positives  
27 227 decreased (from 71.7% to 36.6%) and gram-negatives increased (from 21.7% to 46.9%). The great proportion of  
28 228 gram-negatives in cycles III and IV was unexpected, especially because severe gastrointestinal toxicity (WHO  
29 229 III and IV) decreased from cycle to cycle. *E. coli* and *Klebsiella* species were the most commonly yielded gram-  
30 230 negatives, as has been shown in several earlier series.

42 231           Of the gram-positive microorganisms, CoNSs were the most common finding also in our series  
43 232 in general or in the four different cycles. During the last few decades, much attention has been paid to the  
44 233 importance of *viridans* group streptococci as a cause of bloodstream infections during neutropenia. In several  
45 234 studies, it has been associated with high-dose cytarabine chemotherapy [30, 31, 32] and quinolone prophylaxis  
46 235 [7]. In our study, the incidence of BSIs caused by *viridans* group streptococci was highest during the second  
47 236 cycle with high-dose cytarabine and idarubicin and clearly lower in cycle IV, which also included high-dose  
48 237 cytarabine and amsacrine. Thus, the combination of chemotherapeutics and not only the high-dose cytarabine  
49 238 *per se* seems to be important for BSIs caused by *viridans* group streptococci.

239 It has been recently noted that the knowledge of polymicrobial infections among cancer patients  
1  
2 240 is sparse [33]: In trials involving neutropenic patients, the proportion of polymicrobial BSIs has varied from 8%  
3  
4 241 to 32% [34, 35]. Our overall figure of polymicrobial BSIs was 28.3%. However, there was once again substantial  
5  
6 242 inter-cycle variation. In three-fourths of the episodes, polymicrobial BSIs were caused by two microorganisms.  
7  
8 243 The most common combination included both gram-positive and gram-negative microorganisms and the second  
9  
10 244 most common included at least two gram-positive microorganisms together.

11  
12 245 When polymicrobial BSIs were also taken into account in our study, which included the series of  
13  
14 246 AML patients recruited between 1992 and 2001, the portion of gram-positive microorganisms in BSIs was even  
15  
16 247 higher (79.6%) than in the earlier-mentioned study from the USA: their highest figure (76%) was from the year  
17  
18 248 2000 [8]. The result of 50.9% of gram-negative organisms when polymicrobial BSIs were also included, is quite  
19  
20 249 similar to a recent study [36], patients were also treated without antibiotic prophylaxis. In another study the  
21  
22 250 proportion of gram-negatives was 52% without and 25% with antibiotic prophylaxis [23].  
23

24 251 In conclusion, our AML patients had a high overall BSI rate during chemotherapy regimen-  
25  
26 252 induced neutropenia. However, there was great variation in BSI findings in four treatment cycles with different  
27  
28 253 chemotherapeutics: BSI rate was lowest in cycle I and proportions of microorganisms and polymicrobial BSIs  
29  
30 254 varied greatly from cycle to cycle. Therefore, in order to obtain more precise information concerning BSIs  
31  
32 255 during the intensive chemotherapeutic treatments of AML, the analysis of BSI results should be focused on  
33  
34 256 different chemotherapy cycles rather than by analyzing the overall results.  
35

36 257  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

258 **Acknowledgements**

1  
2 259 No financial support was obtained for this study.  
3

4  
5 260

6  
7 261 **Conflict of Interest**

8  
9 262 The authors declare that they have no conflict of interest.  
10

11  
12 263

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

264 **References**

- 1  
2  
3 265 1. Bodey G P, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships  
4  
5 266 between circulating leukocytes and infection in patients with acute leukemia.  
6  
7  
8 267 Ann Intern Med 64:328-340.  
9
- 10 268 2. Schimpff S, Satterlee W, Young VM, Serpick A (1971) Empiric therapy with  
11  
12  
13 269 carbenicillin and gentamicin for febrile patients with cancer and  
14  
15 270 granulocytopenia. N Engl J Med 284:1061-1065.  
16
- 17  
18 271 3. Baden LR (2005) Prophylactic antimicrobial agents and the importance of  
19  
20 272 fitness. N Engl J Med 353:1052-1054.  
21
- 22 273 4. Cometta A, Zinner S, de Bock R et al (1995) Piperacillin-tazobactam plus  
23  
24  
25 274 amikacin versus ceftazidime plus amikacin as empiric therapy for fever in  
26  
27 275 granulocytopenic patients with cancer. The International Antimicrobial Therapy  
28  
29  
30 276 Cooperative Group of the European Organization for Research and Treatment of  
31  
32 277 Cancer. Antimicrob Agents Chemother 39:445-452.  
33
- 34 278 5. Cometta A, Calandra T, Gaya H et al (1996) Monotherapy with meropenem  
35  
36  
37 279 versus combination therapy with ceftazidime plus amikacin as empiric therapy  
38  
39  
40 280 for fever in granulocytopenic patients with cancer. Antimicrob Agents  
41  
42 281 Chemother 40:1108-1115.  
43
- 44 282 6. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP  
45  
46  
47 283 (1999) Nosocomial bloodstream infections in United States hospitals: a three-  
48  
49 284 year analysis. Clin Infect Dis 29:239-244.  
50
- 51  
52 285 7. Hammond S P, Baden LR (2008) Antibiotic prophylaxis for patients with acute  
53  
54 286 leukemia. Leuk Lymphoma 49:183-193.  
55
- 56 287 8. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MP (2003) Current trends in the  
57  
58  
59 288 epidemiology of nosocomial bloodstream infections in patients with  
60  
61  
62  
63  
64  
65



289 hematological malignancies and solid neoplasms in hospitals in the United  
1 States. Clin Infect Dis 36:1103-1110.

- 2 290  
3  
4 291 9. Zinner SH (1999) Changing epidemiology of infections in patients with  
5 neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin  
6 Infect Dis 29:490-494.  
7 292  
8  
9 293  
10  
11 294 10. Cattaneo C, Quaresmini G, Casari S et al (2008) Recent changes in bacterial  
12 epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli  
13 among patients with haematological malignancies: results of a prospective study  
14 on 823 patients at a single institution. J Antimicrob Chemother 61:721-728.  
15 295  
16  
17 296  
18  
19 297  
20  
21 298 11. Cullen M, Steven N, Billingham L et al (2005) Antibacterial prophylaxis after  
22 chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988-998.  
23  
24 299  
25  
26 300 12. Cullen MH, Billingham LJ, Gaunt CH , Steven NM (2007) Rational selection of  
27 patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 25:4821-  
28 4828.  
29 301  
30  
31 302  
32  
33 303 13. Kinnunen U, Koistinen P, Ohtonen P, Koskela M, Syrjälä H (2008) Influence of  
34 chemotherapy courses on the rate of bloodstream infections during therapy-  
35 induced neutropenia in adult acute myeloid leukemia. Scand J Infect Dis 40:  
36 642-647.  
37 304  
38  
39 305  
40  
41 306  
42  
43 307 14. Koistinen P, Rätty R, Itälä M et al (2007) Long-term outcome of intensive  
44 chemotherapy for adults with de novo acute myeloid leukaemia (AML): the  
45 nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol  
46 78:477-486.  
47 308  
48  
49 309  
50  
51 310  
52  
53 311 15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnik HR,  
54 Sultan C (1985) Proposed revised criteria for the classification of acute myeloid  
55  
56 312  
57  
58  
59  
60  
61  
62  
63  
64  
65

313 leukemia. A report of the French-American-British Cooperative Group. *Ann*  
1  
2 314 *Intern Med* 103:626-629.

3  
4 315 16. Hughes W T, Armstrong D, Bodey GP et al (1990) From the Infectious Diseases  
5  
6  
7 316 Society of America. Guidelines for the use of antimicrobial agents in  
8  
9 317 neutropenic patients with unexplained fever. *J Infect Dis* 61:381-396.

10  
11  
12 318 17. Hughes W T, Armstrong D, Bodey GP et al (1997) 1997 guidelines for the use  
13  
14 319 of antimicrobial agents in neutropenic patients with unexplained fever.  
15  
16  
17 320 Infectious Diseases Society of America. *Clin Infect Dis* 25:551-573.

18  
19 321 18. WHO handbook for reporting results of cancer treatment: World Health  
20  
21  
22 322 Organization, Geneva, Switzerland:WHO offset publication; 1979; no. 48; 45  
23  
24 323 pp.

25  
26 324 19. Brown H, Prescott R (eds.) (2006) *Applied mixed models in medicine*. 455 pp.  
27  
28  
29 325 2nd ed.; John Wiley & Sons, Ltd; Chichester, England.

30  
31 326 20. Bow EJ, Rotstein C, Noskin GA et al (2006) A randomized, open-label,  
32  
33  
34 327 multicenter comparative study of the efficacy and safety of piperacillin-  
35  
36 328 tazobactam and cefepime for the empirical treatment of febrile neutropenic  
37  
38  
39 329 episodes in patients with hematologic malignancies. *Clin Infect Dis* 43:447-459.

40  
41 330 21. Bucaneve G, Micozzi A, Menichetti F et al (2005) Levofloxacin to prevent  
42  
43  
44 331 bacterial infection in patients with cancer and neutropenia. *N Engl J Med*  
45  
46 332 353:977-987.

47  
48  
49 333 22. Gaytán-Martínez J, Mateos-García E, Sánchez-Cortés E, González-Llaven J,  
50  
51 334 Casanova-Cardiel LJ, Fuentes-Allen JL (2000) Microbiological findings in  
52  
53 335 febrile neutropenia. *Arch Med Res* 31:388-392.

54  
55  
56 336 23. Klastersky J, Ameye L, Maertens J et al (2007) Bacteraemia in febrile  
57  
58 337 neutropenic cancer patients. *Int J Antimicrob Agents* 30 Suppl 1:S51-9.

- 338 24. Madani TA (2000) Clinical infections and bloodstream isolates associated with  
1 fever in patients undergoing chemotherapy for acute myeloid leukemia. *Infection*  
2 339 28:367-373.  
3  
4 340  
5  
6  
7 341 25. Pizzo PA (1993) Management of fever in patients with cancer and treatment-  
8 induced neutropenia. *N Engl J Med* 328:1323-1332.  
9 342  
10  
11 343 26. Kinnunen U, Syrjälä H, Koskela M, Kujala P, Koistinen P (1996) Continuous-  
12 monitoring blood culture screening system improves the detection of bacteremia  
13 344 in neutropenic patients. *Scand J Infect Dis* 28:287-292.  
14  
15 345  
16  
17 346 27. Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM  
18 (2003) Prospective evaluation of the epidemiology, microbiology, and outcome  
19 347 of bloodstream infections in hematologic patients in a single cancer center. *Eur J*  
20 Clin Microbiol Infect Dis 22:137-143.  
21  
22 348  
23  
24 349 28. Sundstrom GM, Wahlin A, Nordin-Andersson I, Suhr OB (1998) Intestinal  
25 permeability in patients with acute myeloid leukemia. *Eur J Haematol* 61:250-  
26 254.  
27  
28 350 29. Blijlevens NMA, van't Land B, Donnely JP, M'Rabet L, de Pauw PE (2004)  
29 Measuring mucosal damage induced by cytotoxic therapy. *Support Care Cancer*  
30 351 12: 227 – 233.  
31  
32 352  
33  
34 353 30. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P (1994)  
35 Bacteremia due to viridans streptococcus in neutropenic patients with cancer:  
36 354 clinical spectrum and risk factors. *Clin Infect Dis* 18:25-31.  
37  
38 355  
39 356 31. Cordonnier C, Buzyn A, Leverger G, Herbrecht R, Hunault M, Leclercq R,  
40 Bastuji-Garin S (2003) Epidemiology and risk factors for gram-positive coccal  
41 357 infections in neutropenia: toward a more targeted antibiotic strategy. *Clin Infect*  
42 Dis 36:149-158.  
43  
44 358  
45  
46 359  
47  
48 360  
49  
50  
51 361  
52  
53 362  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 363 32. Kern W, Linzmeier K, Kurrle E (1989) Antimicrobial susceptibility of viridans  
1 group streptococci isolated from patients with acute leukemia receiving  
2 364 ofloxacin for antibacterial prophylaxis. *Infection* 17:396-397.  
3  
4 365  
5  
6  
7 366 33. Rolston KV, Bodey GP, Safdar A (2007) Polymicrobial infection in patients  
8 with cancer: an underappreciated and underreported entity. *Clin Infect Dis*  
9 367 45:228-233.  
10  
11 368  
12  
13 369 34. Giamarellou H, Bassaris HP, Petrikos G et al (2000) Monotherapy with  
14 intravenous followed by oral high-dose ciprofloxacin versus combination  
15 370 therapy with ceftazidime plus amikacin as initial empiric therapy for  
16 granulocytopenic patients with fever. *Antimicrob Agents Chemother* 44:3264-  
17 371 3271.  
18  
19 372  
20  
21 373  
22  
23 374 35. Harter C, Schulze B, Goldschmidt H et al (2006) Piperacillin/tazobactam vs  
24 ceftazidime in the treatment of neutropenic fever in patients with acute leukemia  
25 or following autologous peripheral blood stem cell transplantation: a prospective  
26 375 randomized trial. *Bone Marrow Transplant* 37:373-379.  
27  
28  
29 376  
30  
31 377 36. Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM  
32 (2006) Comparative study of clinical characteristics of neutropenic and non-  
33 neutropenic adult cancer patients with bloodstream infections. *Eur J Clin*  
34 378 *Microbiol Infect Dis* 25:1-7.  
35  
36 379  
37  
38  
39 380  
40  
41 381  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**TABLE 1. Length of hospital stay, duration of febrile episodes and neutropenia, the serum peak value of C-reactive protein, incidence rate (IR) of blood stream infections (BSI) and odds ratios (OR) for the risk of BSI and gastrointestinal toxicity in different treatment cycles (cycle I as a reference);**

	Cycle I <sup>a</sup>	Cycle II	Cycle III	Cycle IV	P <sup>b</sup>
Hospital days <sup>c</sup>	30 (28-36)	37 (31-44)	34 (27-44)	31 (25-38)	<.001
IR of BSIs / 1 000 days (95% CI) <sup>d</sup>	6.8 (5.4 to 8.6)	15.6 (13.4 to 18.1)	15.8 (13.3 to 18.8)	17.6 (13.8 to 22.2)	-
Neutrophils < 500/ $\mu$ L, days <sup>c</sup>	24 (20-28)	26 (19-32)	25 (17-37)	22 (18-29)	<.001
IR of BSIs/ 1 000 neutropenic days (95% CI) <sup>d</sup>	9.2 (7.2 to 11.6)	23.2 (20.0 to 26.9)	21.3 (17.8 to 25.3)	23.6 (18.4 to 29.7)	-
Temperature $\geq$ 38°C, days <sup>b</sup>	9 (5-14)	7 (3-11)	6 (3-10)	7 (3-9)	<.001
C-reactive protein (mg/L, peak value) <sup>c</sup>	164 (119-230)	161 (115-206)	158 (113-210)	160 (107-205)	.30
OR for BSI (95% CI) <sup>d</sup> P <sup>e</sup>	1.0	5.8 (4.1 to 8.2)	5.5 (3.8 to 8.0)	4.8 (3.1 to 7.4)	
		<.001	<.001	<.001	
OR for gi-toxicity, grade III and IV (95% CI) <sup>d</sup> P <sup>e</sup>	1.0	0.65 (0.43 to 0.98)	0.43 (0.27 to 0.70)	0.33 (0.17 to 0.62)	
		.041	<.001	<.001	

1. <sup>a</sup> chemotherapeutics: cycle I; idarubicin, cytarabine and thioguanine, cycle II; high-dose cytarabine and idarubicin, cycle III; etoposide cytarabine and mitoxantrone, Cycle IV; amsacrine and high-dose cytarabin.

<sup>b</sup> *P*-time according to Linear mixed model.

<sup>c</sup> values are medians with 25<sup>th</sup> -75<sup>th</sup> percentiles.

<sup>d</sup> values are means with 95% confidence intervals (95%CI).

<sup>e</sup> *P*-time according to the generalized linear mixed model (7).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**TABLE 2. Detected microorganisms during different chemotherapy cycles; the number (%) of positive blood cultures per treatment episodes in each cycle.**

	Cycle I (n= 323)	Cycle II (n=292)	Cycle III (n=219)	Cycle IV (n=122)	All (n=956)
<b>Blood culture positive, number (%)</b>	<b>72 (22.3)</b>	<b>180 (61.6)</b>	<b>133 (60.7)</b>	<b>71 (58.2)</b>	<b>456 (47.7)</b>
<b>Monomicrobial</b>	<b>60 (83.3)</b>	<b>113 (62.2)</b>	<b>105 (78.9)</b>	<b>49 (69.0)</b>	<b>327 (71.7)</b>
Gram-positive	43 (71.7)	71 (62.8)	56 (53.3)	26 (36.6)	197 (43.2)
- CoNS	23 (38.3)	28 (24.8)	34 (32.4)	15 (30.6)	100 (30.6)
- VGS	5 (8.3)	23 (20.4)	12 (11.4)	6 (12.2)	46 (14.1)
- <i>Enterococci</i>	7 (11.7)	9 (8.0)	7 (6.7)	4 (8.2)	27 (8.3)
Gram-negative	13 (21.7)	41 (36.3)	48 (45.7)	23 (46.9)	124 (37.9)
- <i>E. coli</i>	3 (5.0)	7 (6.2)	15 (14.3)	12 (24.5)	37 (11.3)
- <i>Klebsiella sp.</i>	2 (3.3)	16 (14.2)	20 (19.0)	5 (10.2)	43 (13.1)
- <i>Enterobacter sp.</i>	1 (1.7)	7 (6.2)	6 (5.7)	2 (4.1)	16 (4.9)
- <i>Pseudomonas aeruginosa</i>	3 (5.0)	7 (6.2)	1 (1.0)	3 (6.1)	14 (4.3)
Anaerobic microorganisms	3 (5.0)	-	-	-	3 (0.9)
Yeast	1 (1.7)	1 (0.9)	1 (1.0)	-	3 (0.9)
<b>Polymicrobial</b>	<b>12 (16.7)</b>	<b>67 (37.2)</b>	<b>28 (21.1)</b>	<b>22 (31.0)</b>	<b>129 (28.3)</b>

**NOTE.** CoNS, coagulase-negative staphylococci; VGS, viridans group streptococci. Among gram-positives and gram-negatives, only three most common microbes are mentioned, and among gram-negatives also the presence of *Pseudomonas*.

**TABLE 3. Characterization of microorganisms of polymicrobial bloodstream infections in different chemotherapy cycles**

<b>Blood stream infections</b>	<b>Cycle I (n=12)</b>	<b>Cycle II (n=67)</b>	<b>Cycle III (n=28)</b>	<b>Cycle IV (n=22)</b>	<b>All (n=129)</b>
Number of microorganisms					
- Two	8 (66.7)	49 (73.1)	24 (85.7)	16 (72.7)	97 (75.2)
- More than two	4 (33.3)	18 (26.9)	4 (14.3)	6 (27.3)	32 (24.8)
Combinations of microorganisms					
- Gram-positives only	5 (41.7)	27 (40.3)	5 (17.9)	3 (13.6)	40 (31.0)
- Gram-positive and anaerobic	-	4 (6.0)	-	-	4 (3.1)
- Gram-positive and yeast	-	1 (1.5)	-	2 (9.1)	3 (2.3)
- Gram-positive and gram-negative	6 (50.0)	28 (41.8)	18 (64.3)	11 (50.0)	63 (48.8)
- Gram-negatives only	1 (8.3)	4 (6.0)	3 (10.7)	5 (22.7)	13 (10.1)
- Gram-negative and yeast	-	3 (4.5)	2 (7.1)	1 (4.5)	6 (4.7)



## Figure legends

**FIGURE 1.** Positive blood culture findings (%) during four chemotherapy cycles among adult acute myeloid leukemia patients. Gram-positive, gram-negative and other micro-organisms (yeast, anaerobes and polymicrobial). Gastrointestinal toxicity grade III and IV according to the WHO. The difference between positive blood cultures in cycle I vs. the other three,  $P < 001$  each (multilevel generalized linear model). Cycle I; idarubicin, cytarabine and thioguanine, cycle II; high-dose cytarabine and idarubicin, cycle III; etoposide, cytarabine and mitoxantrone and cycle IV; amsacrine and high-dose cytarabine.

**FIGURE 2.** Comparison of positive blood culture findings in cycle I between patients having (Inf +) or not having infection (inf -) at the time of diagnosis of AML ( $P = .17$ ), and in cycle II the comparison between those patients having achieved remission (rem +) and those still having an active disease (rem -,  $P = .11$ , Fisher's Exact Test, two-tailed).




Figure 1.




Figure 2.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65